FDA Approves First Muscle-Targeted Treatment for Spinal Muscular Atrophy

Administered as a 10 mg/kg intravenous infusion every four weeks, the new treatment can be provided at hospitals, infusion centers, or within the home setting. Kenneth Hobby, president of the nonprofit advocacy group Cure SMA, described the approval as a major advancement that offers the potential for improved physical outcomes and increased independence for patients. The development follows decades of research and clinical trial participation supported by more than $92 million in funding from the organization.

Cure SMA is now shifting its focus toward ensuring patient access and providing clinical guidance. The group plans to host an educational webinar on September 30, 2026, to help families navigate implementation and treatment decisions. Jackie Glascock, the organization’s chief scientific officer, emphasized the necessity of partnering with Scholar Rock and healthcare providers to ensure the therapy reaches those who need it most. Spinal muscular atrophy remains a progressive neurodegenerative disease, affecting approximately one in 15,000 births in the United States.